| 2.56 -0.15 (-5.54%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.36 | 1-year : | 3.93 |
| Resists | First : | 2.88 | Second : | 3.36 |
| Pivot price | 2.47  |
|||
| Supports | First : | 2.48 | Second : | 2.23 |
| MAs | MA(5) : | 2.64 |
MA(20) : | 2.47 |
| MA(100) : | 3.51 |
MA(250) : | 7.88 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 74.5 |
D(3) : | 82.6 |
| RSI | RSI(14): 51.4 |
|||
| 52-week | High : | 25.7 | Low : | 2.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ICU ] has closed below upper band by 35.2%. Bollinger Bands are 64.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 41 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.6 - 2.62 | 2.62 - 2.63 |
| Low: | 2.46 - 2.47 | 2.47 - 2.49 |
| Close: | 2.53 - 2.56 | 2.56 - 2.58 |
SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.
Mon, 23 Feb 2026
ICU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fri, 13 Feb 2026
Investors report 9.99% SeaStar Medical (ICU) ownership via warrants - Stock Titan
Wed, 14 Jan 2026
SeaStar Medical Holding (ICU) Price Target Increased by 900.00% to 10.20 - Nasdaq
Tue, 23 Dec 2025
SeaStar Medical stock tumbles after announcing 1-for-10 reverse split - Investing.com
Tue, 23 Dec 2025
SeaStar Medical Holding Corporation Announces 1-for-10 Reverse Stock Split Effective January 5, 2026 - Quiver Quantitative
Fri, 19 Dec 2025
What's Going On With Shares Of SeaStar Medical Today? - SeaStar Medical Holding (NASDAQ:ICU) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3.56e+006 (%) |
| Held by Institutions | 2.5 (%) |
| Shares Short | 100 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 955.7 % |
| Return on Equity (ttm) | -86.6 % |
| Qtrly Rev. Growth | 881000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -11.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.75 |
| Dividend | 0 |
| Forward Dividend | 154400 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|